Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77,331,078
-
Total 13F shares
-
9,020,019
-
Share change
-
+2,752,566
-
Total reported value
-
$82,987,000
-
Price per share
-
$9.20
-
Number of holders
-
40
-
Value change
-
+$29,134,582
-
Number of buys
-
21
-
Number of sells
-
14
Institutional Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q2 2018
As of 30 Jun 2018,
Xenon Pharmaceuticals Inc. - Common Stock (XENE) was held by
40 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,020,019 shares.
The largest 10 holders included
Capital World Investors, venBio Select Advisor LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., BVF INC/IL, ORBIMED ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, Granite Point Capital Management, L.P., Schonfeld Strategic Advisors LLC, ACUTA CAPITAL PARTNERS, LLC, and SPHERA FUNDS MANAGEMENT LTD..
This page lists
40
institutional shareholders reporting positions in this security
for the Q2 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.